Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Upper Tract Urothelial Cancer
Do people extrapolate data from the NIAGARA trial regarding peri-operative durvalumab cisplatin based chemo to upper tract urothelial carcinoma?
Related Questions
Which patients with prostate cancer do you consider to be good candidates for salvage local treatment after radiation therapy?
Would you give any adjuvant therapy (chemo, immunotherapy and/or radiation) to a patient with pure small cell cancer of the urinary bladder who received neoadjuvant cisplatin and etoposide but had pN+ and residual invasive disease on cystectomy?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
Would the occurrence of obvious tumor rupture/spillage intraoperatively impact your decision for adjuvant systemic therapy after resection of either clear cell RCC or papillary RCC?
What data support the use of continuing GnRH therapy "backbone" in metastatic castration resistant prostate cancer (mCRPC) receiving additional therapies?
What are your top takeaways in GU Cancers from ESMO 2024?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
How do you decide whether to add docetaxel to ADT/abiraterone or ADT/darolutamide in patients with mCSPC in the era of PSMA PET staging?
